{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F0522c442-0947-4be3-b726-2c4b15db36fa","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/0522c442-0947-4be3-b726-2c4b15db36fa\"></iframe>","title":"The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer","description":"\n        <p>Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations, moderated by Dr Neil Love. Produced by Research To Practice. </p>\n\n<p>CME information and select publications <a href=\"https://www.researchtopractice.com/WCLC2024/NontargetedLung\" rel=\"nofollow\">here</a>.</p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/a0693836-f0c7-4a65-9785-c7c0ac7266aa/cover.jpg"}